17 active not recruiting, 12 recruiting, 6 completed, 1 withdrawn. 18 Phase 3, 16 Phase 2, 4 Phase 1, 1 Not applicable.
Follow MB02: new trials by email Literature Review of MB02 trials Research Report on MB02
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-29 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial Chemotherapy, Computed Tomography, Internet-Based Intervention - Glioma, Recurrent Glioma | Not applicable | Recruiting | Mayo Clinic | 202 | 2025-09-12 | 2026-08-10 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2025-06-23 | 2026-09-09 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer Atezolizumab, Bevacizumab, Biospecimen Collection - Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2022-12-07 | 2026-08-13 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Atezolizumab, Bevacizumab, Biopsy Procedure - Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 65 | 2022-06-10 | 2026-10-28 |
| Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Atezolizumab, Bevacizumab, Biospecimen Collection - Peritoneal Malignant Mesothelioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2022-03-22 | 2026-10-26 |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 300 | 2020-12-28 | 2026-10-27 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Anetumab Ravtansine, Bevacizumab, Paclitaxel - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2018-10-12 | 2026-10-13 |
| Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2018-06-27 | 2026-08-13 |
| Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study Atezolizumab, Bevacizumab, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2018-01-19 | 2026-10-26 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Bevacizumab, Cediranib, Cediranib Maleate - Recurrent Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2017-12-07 | 2026-09-15 |
| A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers MB02, US licenced Avastin®, EU approved Avastin® - Healthy Volunteers | Phase 1 | Completed | mAbxience Research S.L. | 114 | 2017-12-07 | 2021-03-23 |
Showing 20 of 36. Sign in to see all of them.
Fallopian Tube Neoplasms (5) · Ovarian Neoplasms (5) · Colorectal Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Glioblastoma (3) · Lung Neoplasms (3) · Breast Neoplasms (2) · Brenner Tumor (2) · Carcinoma (2) · Lymphoid Interstitial Pneumonia (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1)
National Cancer Institute (NCI) (29) · City of Hope Medical Center (2) · NRG Oncology (2) · ECOG-ACRIN Cancer Research Group (1) · Mayo Clinic (1) · mAbxience Research S.L. (1)
United States (34) · Canada (5) · Puerto Rico (5) · South Africa (4) · Peru (3) · Japan (2) · South Korea (2) · Ireland (1) · United Kingdom (1)
Aaron S Mansfield (1) · Aarti Bhatia (1) · Al B Benson (1) · Alice P Chen (1) · Amanda N Fader (1) · Antoinette J Wozniak (1) · Carol Aghajanian (1) · David Hsieh (1) · David M Gershenson (1) · Frank S Hodi (1) · Heather A Wakelee (1) · Helena A Yu (1) · Hope S Rugo (1)
PMID 37185961, PMID 25092775, PMID 26933849, PMID 27138575, PMID 28384065, PMID 28438473, PMID 28646344, PMID 29129443, PMID 29789969, PMID 30040523, PMID 30054636, PMID 31276981, PMID 31618129, PMID 31722153, PMID 33067126, PMID 33541735, PMID 34616010, PMID 34726788, PMID 35044810, PMID 35226083, PMID 35658479, PMID 37672694, PMID 37673112, PMID 41666849, PMID 41999612, PMID 42525921, PMID 42550611
U10CA180868 (11), U10CA180820 (9), U10CA021115 (5), U10CA027469 (4), U10CA180821 (3), P30CA033572 (2), U10CA031946 (2), U10CA032102 (2), U10CA180888 (2), UM1CA186689 (2), UM1CA186709 (2), P30CA006516 (1), U01CA062490 (1), U01CA076576 (1), U24CA196172 (1)